Skip to main content

Table 1 Patient characteristics

From: Double-blind, randomized, placebo-controlled study to evaluate erenumab-specific central effects: an fMRI study

Patient characteristics

Verum

Placebo

Statistics

Number

21

19

 

Female, % (n)

90.48 (19)

78.95 (15)

a0.3976

Age, mean ± SD (range), in years

39.1 ± 12,77 (19-62)

41.58 ± 11,43 (22-60)

b0.5202

Migraine with and without aura, n

8

10

a0.5254

Migraine without aura, n

13

9

Chronic migraine (ICHD-3), % (n)

42.86 (9)

21.05 (4)

a0.1861

Episodic migraine (ICHD-3), % (n)

57.14 (12)

78.95 (15)

Baseline headache frequency, mean± SD (range), days/month

15.68 ± 8.29 (4-30)

13.26 ± 6.51 (6-28)

c0.3775

Absolute reduction in monthly headache frequency after month two mean± SD (range), days/month

1.69 ± 3.88 (-6-9)

0.98 ± 3.49 (-6-11)

b0.5302

Responder 30% / 50%, % (n)

33.33 (7) / 19.05 (4)

21.05 (4) / 5.26 (1)

a1.00

  1. Abbreviation ICHD-3 International Classification of Headache Disorders, 3rd edition
  2. aFisher's Exact Test
  3. bTwo Sample t-test
  4. cWilcoxon rank sum test with continuity correction